XML 62 R49.htm IDEA: XBRL DOCUMENT v3.4.0.3
Share-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Income Tax Benefit Recognized for our Share-Based Compensation Arrangements

Compensation cost charged against income, primarily selling, general and administrative expense, and the income tax benefit recognized for our share-based compensation arrangements is included below:

 

     Years Ended December 31,  
     2015      2014      2013  
     (In thousands)  

Total share-based compensation cost

   $ 17,745       $ 18,858       $ 14,854   

Income tax benefit

     6,867         7,334         5,777   

Fair Values for SARs and Stock Options Estimated on Grant Date Using Black-Scholes-Merton Option-Pricing Formula Which Incorporates Assumptions

We recognize compensation cost for all awards based on their fair values. The fair values for SARs and stock options are estimated on the grant date using the Black-Scholes-Merton option-pricing formula which incorporates the assumptions noted in the following table. Expected volatility is based on historical volatility, and expected term is based on historical exercise patterns of option holders. The fair value of restricted stock units with service vesting conditions or performance vesting conditions is the closing market price of our common stock on the date of grant. We estimate the fair value of certain restricted stock units with market conditions using a Monte Carlo simulation valuation model with the assistance of a third party valuation firm. Compensation costs for awards with service conditions are amortized to expense using the straight-line method. Compensation costs for awards with performance conditions and graded vesting are amortized to expense using the graded attribution method.

 

     Years Ended December 31,  
     2015     2014     2013  
     (In thousands, except weighted average fair
value and assumptions)
 

Weighted-average fair value of SARs and options granted

   $ 31.22      $ 35.46      $ 24.63   

Total intrinsic value of SARs converted and options exercised

     14,697        24,023        47,058   

Cash received for options exercised

     30        48        14,030   

Tax benefit related to share-based compensation

     5,050        6,859        10,734   

Weighted-average fair value of restricted stock shares and units granted

     96.52        72.46        50.38   

Total fair value of restricted stock shares and units vested

     7,696        7,888        9,032   

Expected volatility

     35.66     52.63     53.94

Expected term (in years)

     5.7        5.8        6.1   

Risk-free rate

     1.59     1.79     1.04

Dividend yield

     0.22     0.28     0.40
Summary of Share Based Compensation Activity

 

     SARs and Stock Options     Restricted Shares and Units  
     Number     Weighted-
Average
Exercise
Price
     Weighted-
Average
Remaining
Contractual
Term
     Aggregate
Intrinsic
Value
    Number     Weighted-
Average
Grant-Date
Fair Value
 
     (In thousands, except exercise prices, fair values, and contractual terms)  

Outstanding at January 1, 2015

     1,305      $ 44.60              493      $ 54.76   

Granted

     236        88.79              183        96.52   

Exercised or converted

     (320     40.03              (178     43.11   

Forfeited or expired

     (32     73.60              (34     70.99   
  

 

 

   

 

 

         

 

 

   

 

 

 

Outstanding at December 31, 2015

     1,189      $ 53.80         7.0       $ (7,280     464      $ 74.50   
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Vested or expected to vest at December 31, 2015

     1,169      $ 53.51         7.0       $ (6,811    

Exercisable or convertible at December 31, 2015

     730        41.06         6.0         4,831       

At December 31, 2015, the total unrecognized compensation cost related to all nonvested awards was $22.6 million. That cost is expected to be recognized over a weighted-average period of 1.8 years.